A Study to Assess Safety, Tolerability and PK of AZD2171 and Chemotherapy on Patients With Solid Tumors

Part of paid clinical trials in Ann Arbor, Michigan.

Sponsor
AstraZeneca
Study ID
NCT00502567
Phase
PHASE1
Status
Completed

Conditions

  • Advanced Solid Tumor

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

A multicentre, 2-part study to assess the safety and tolerability of once daily oral doses of AZD2171 when administered with various anticancer regimens (part A) and to confirm the tolerability of its combination with FOLFOX (part B).

Key Dates

Start date
Jan 31, 2005
Status verified
Jul 2011
Primary completion
Nov 30, 2007
Completion
Jun 30, 2011

Study Design

Enrollment
104 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Primary Outcome Measure

Determine the safety and tolerability of once daily oral doses of AZD2171 when given in combination with one of these anticancer regimens; FOLFOX, Pemetrexed, Irinotecan, Docetaxel [ Time Frame: After 5 weeks of treatment ]

Locations (3)

FacilityCityStateZIPSite coordinators
Research SiteAnn ArborMichigan--
Research SiteDetroitMichigan--
Research SiteNashvilleTennessee--

Find similar trials in Ann Arbor, MI

By research site
Research Site· Ann Arbor, MIResearch Site· Detroit, MIResearch Site· Nashville, TN

Related Studies